Although the organoruthenium plecstatin‐1 (IF6) was identified as a plectin targeting metal‐based candidate, no significant effects on the distribution or expression of plectin were observed upon treatment.[18b, 23] Fitting to its role as a cytolinker, plectin‐targeting by plecstatin‐1 was shown to reduce the invasiveness of cancer cells in a 3D in vitro model.[18b]. This evidence concerns the gene PLEC and cancer.